Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
<p>Persistence of Tcm-derived CD19-CAR T cells</p>
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awduron Eraill: | , , , , , , , , , , , , , , , , , , , , |
| Cyhoeddwyd: |
2025
|
| Pynciau: | |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
| _version_ | 1849927633281744896 |
|---|---|
| author | Ibrahim Aldoss (15055961) |
| author2 | Samer K. Khaled (15055964) Xiuli Wang (15055967) Joycelynne Palmer (15055970) Yan Wang (15055973) Jamie R. Wagner (15055976) Mary C. Clark (15055979) Jennifer Simpson (15055982) Jinny Paul (15055985) Vibhuti Vyas (15055988) Sheng-Hsuan Chien (15055991) Anthony Stein (15055994) Vinod Pullarkat (15047900) Amandeep Salhotra (15055997) Monzr M. Al Malki (15056000) Ahmed Aribi (15056003) Karamjeet Sandhu (15056006) Sandra H. Thomas (15056009) Lihua E. Budde (15056012) Guido Marcucci (11252666) Christine E. Brown (15056015) Stephen J. Forman (15056018) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Ibrahim Aldoss (15055961) Samer K. Khaled (15055964) Xiuli Wang (15055967) Joycelynne Palmer (15055970) Yan Wang (15055973) Jamie R. Wagner (15055976) Mary C. Clark (15055979) Jennifer Simpson (15055982) Jinny Paul (15055985) Vibhuti Vyas (15055988) Sheng-Hsuan Chien (15055991) Anthony Stein (15055994) Vinod Pullarkat (15047900) Amandeep Salhotra (15055997) Monzr M. Al Malki (15056000) Ahmed Aribi (15056003) Karamjeet Sandhu (15056006) Sandra H. Thomas (15056009) Lihua E. Budde (15056012) Guido Marcucci (11252666) Christine E. Brown (15056015) Stephen J. Forman (15056018) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ibrahim Aldoss (15055961) Samer K. Khaled (15055964) Xiuli Wang (15055967) Joycelynne Palmer (15055970) Yan Wang (15055973) Jamie R. Wagner (15055976) Mary C. Clark (15055979) Jennifer Simpson (15055982) Jinny Paul (15055985) Vibhuti Vyas (15055988) Sheng-Hsuan Chien (15055991) Anthony Stein (15055994) Vinod Pullarkat (15047900) Amandeep Salhotra (15055997) Monzr M. Al Malki (15056000) Ahmed Aribi (15056003) Karamjeet Sandhu (15056006) Sandra H. Thomas (15056009) Lihua E. Budde (15056012) Guido Marcucci (11252666) Christine E. Brown (15056015) Stephen J. Forman (15056018) |
| dc.date.none.fl_str_mv | 2025-11-25T13:07:04Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30707519 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplemental_Figure_S2_from_Favorable_Activity_and_Safety_Profile_of_Memory-Enriched_CD19-Targeted_Chimeric_Antigen_Receptor_T-Cell_Therapy_in_Adults_with_High-Risk_Relapsed_Refractory_ALL/30707519 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Hematological Cancers Leukemias Immunotherapy Cellular immunotherapy Engineered/CAR T cells |
| dc.title.none.fl_str_mv | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Persistence of Tcm-derived CD19-CAR T cells</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_c3932840b189ad3cf69a271ea9837a09 |
| identifier_str_mv | 10.1158/1078-0432.30707519 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30707519 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALLIbrahim Aldoss (15055961)Samer K. Khaled (15055964)Xiuli Wang (15055967)Joycelynne Palmer (15055970)Yan Wang (15055973)Jamie R. Wagner (15055976)Mary C. Clark (15055979)Jennifer Simpson (15055982)Jinny Paul (15055985)Vibhuti Vyas (15055988)Sheng-Hsuan Chien (15055991)Anthony Stein (15055994)Vinod Pullarkat (15047900)Amandeep Salhotra (15055997)Monzr M. Al Malki (15056000)Ahmed Aribi (15056003)Karamjeet Sandhu (15056006)Sandra H. Thomas (15056009)Lihua E. Budde (15056012)Guido Marcucci (11252666)Christine E. Brown (15056015)Stephen J. Forman (15056018)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsHematological CancersLeukemiasImmunotherapyCellular immunotherapyEngineered/CAR T cells<p>Persistence of Tcm-derived CD19-CAR T cells</p>2025-11-25T13:07:04ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30707519https://figshare.com/articles/figure/Supplemental_Figure_S2_from_Favorable_Activity_and_Safety_Profile_of_Memory-Enriched_CD19-Targeted_Chimeric_Antigen_Receptor_T-Cell_Therapy_in_Adults_with_High-Risk_Relapsed_Refractory_ALL/30707519CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307075192025-11-25T13:07:04Z |
| spellingShingle | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Ibrahim Aldoss (15055961) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Hematological Cancers Leukemias Immunotherapy Cellular immunotherapy Engineered/CAR T cells |
| status_str | publishedVersion |
| title | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| title_full | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| title_fullStr | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| title_full_unstemmed | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| title_short | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| title_sort | Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Hematological Cancers Leukemias Immunotherapy Cellular immunotherapy Engineered/CAR T cells |